MX2007008158A - Tratamiento de trastornos por el virus de hepatitis c. - Google Patents

Tratamiento de trastornos por el virus de hepatitis c.

Info

Publication number
MX2007008158A
MX2007008158A MX2007008158A MX2007008158A MX2007008158A MX 2007008158 A MX2007008158 A MX 2007008158A MX 2007008158 A MX2007008158 A MX 2007008158A MX 2007008158 A MX2007008158 A MX 2007008158A MX 2007008158 A MX2007008158 A MX 2007008158A
Authority
MX
Mexico
Prior art keywords
treatment
hcv
disorders
hcv disorders
hepatitis
Prior art date
Application number
MX2007008158A
Other languages
English (en)
Spanish (es)
Inventor
Gilles Feutren
Volker Brinkmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2007008158A publication Critical patent/MX2007008158A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2007008158A 2005-01-04 2006-01-02 Tratamiento de trastornos por el virus de hepatitis c. MX2007008158A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0500020.3A GB0500020D0 (en) 2005-01-04 2005-01-04 Organic compounds
PCT/EP2006/000003 WO2006072562A1 (fr) 2005-01-04 2006-01-02 Traitement des troubles lies au vhc

Publications (1)

Publication Number Publication Date
MX2007008158A true MX2007008158A (es) 2007-07-24

Family

ID=34179124

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007008158A MX2007008158A (es) 2005-01-04 2006-01-02 Tratamiento de trastornos por el virus de hepatitis c.

Country Status (12)

Country Link
US (2) US20080207567A1 (fr)
EP (2) EP2351560A1 (fr)
JP (1) JP2008526714A (fr)
KR (1) KR20070091316A (fr)
CN (2) CN101879152A (fr)
AU (2) AU2006204524B8 (fr)
BR (1) BRPI0606370A2 (fr)
CA (1) CA2592883A1 (fr)
GB (1) GB0500020D0 (fr)
MX (1) MX2007008158A (fr)
RU (1) RU2007129673A (fr)
WO (1) WO2006072562A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124210A1 (fr) * 2007-02-14 2008-10-16 Emory University Procédés et compositions destinés à traiter ou prévenir une infection en utilisant des agents de séquestration des leucocytes
US20110275673A1 (en) * 2008-09-19 2011-11-10 Yibin Xiang Inhibitors of sphingosine kinase 1
WO2012109108A1 (fr) 2011-02-07 2012-08-16 Biogen Idec Ma Inc. Agents modulant s1p
US9499485B2 (en) 2012-08-06 2016-11-22 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
WO2014025708A1 (fr) 2012-08-06 2014-02-13 Biogen Idec Ma Inc. Composés étant des agents de modulation de s1p et/ou des agents de modulation d'atx
EP2925721B1 (fr) 2012-11-20 2017-06-07 Biogen MA Inc. Agents modulant s1p et/ou atx
ES2749467T3 (es) 2012-11-20 2020-03-20 Biogen Ma Inc Agentes moduladores de S1p y/o ATX
US9765016B2 (en) 2013-01-29 2017-09-19 Biogen Ma Inc. S1P modulating agents
EP2970302A1 (fr) 2013-03-15 2016-01-20 Biogen MA Inc. Modulateurs de s1p et/ou de l'atx
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH640725A5 (de) 1979-10-08 1984-01-31 Rudolf Schweizer Anlage zur fussreflexzonen-massage.
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
US4880784A (en) 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
DE69132332T2 (de) 1990-04-06 2000-11-30 Genelabs Tech Inc Hepatitis c-virus-epitope
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ES2126658T3 (es) 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
US5496546A (en) 1993-02-24 1996-03-05 Jui H. Wang Compositions and methods of application of reactive antiviral polyadenylic acid derivatives
EP0773029A4 (fr) 1993-07-19 1997-09-03 Tokyo Tanabe Co Inhibiteur de proliferation du virus de l'hepatite c
DE4447588C2 (de) 1994-05-03 1997-11-20 Omer Osama Dr Dr Med Pflanzliches Arzneimittel zur Behandlung von chronischen und allergischen Rhino-Sino-Bronchitiden
WO1996006068A1 (fr) 1994-08-22 1996-02-29 Yoshitomi Pharmaceutical Industries, Ltd. Compose benzenique et son utilisation medicale
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5916878A (en) 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
WO1997024112A1 (fr) * 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. Preparation a usage externe
JP2000506010A (ja) 1996-02-29 2000-05-23 イミューソル インコーポレイテッド Ｃ型肝炎ウイルスリボザイム
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
JPH09315980A (ja) 1996-05-24 1997-12-09 Kirin Brewery Co Ltd エイズ発症予防薬および進行抑制薬
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5837257A (en) 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
JP3927630B2 (ja) 1996-09-27 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウイルス感染症の予防・治療剤
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
JP4045364B2 (ja) 1997-04-04 2008-02-13 田辺三菱製薬株式会社 ２−アミノプロパン−１，３−ジオール化合物、その医薬としての用途およびその合成中間体
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
EP1009732B1 (fr) 1997-06-30 2003-05-21 MERZ + CO. GmbH & Co. 1-aminoalkylcyclohexanes antagonistes du recepteur de nmda
ES2234144T3 (es) 1997-08-11 2005-06-16 Boehringer Ingelheim (Canada) Ltd. Analogos de peptidos inhibidores de la hepatitis c.
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
EP2390257A1 (fr) 1998-02-25 2011-11-30 Emory University 2'-Fluoronucléosides
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
NZ508797A (en) 1998-06-24 2004-02-27 Innogenetics N Particles of HCV envelope proteins: use for vaccination
DE69925918T2 (de) 1998-07-27 2006-05-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketosäure-derivate als hemmstoffe von polymerasen
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
MXPA01009829A (es) 1999-04-02 2003-07-21 Conoco Inc Metodo para inversion de datos magneticos y de gravedad utilizando metodos de vector y tensor con formacion de imagenes sismicas y prediccion de geopresion para petroleo, gas y produccion y exploracion mineral.
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
WO2001060315A2 (fr) 2000-02-18 2001-08-23 Shire Biochem Inc. Methode de traitement ou de prevention d'infections a flavivirus a l'aide d'analogues nucleosidiques
KR20100003313A (ko) 2000-04-13 2010-01-07 파마셋 인코포레이티드 간염 바이러스 감염 치료를 위한 3'- 또는 2'-하이드록시메틸 치환된 뉴클레오시드 유도체
AU2001261377A1 (en) 2000-05-10 2001-11-20 Smith Kline Beecham Corporation Novel anti-infectives
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
YU92202A (sh) 2000-05-26 2006-01-16 Idenix (Cayman) Limited Metode i smeše za lečenje flavi virusa i pesti virusa
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
WO2002008251A2 (fr) 2000-07-21 2002-01-31 Corvas International, Inc. Nouveaux peptides utilises comme inhibiteurs de ns3-serine protease du virus de l'hepatite c
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
HUP0303358A3 (en) 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
AU2001255070A1 (en) 2000-08-28 2002-03-13 Jin-Sub Kim Generator of two-wheeled vehicle and lighting system thereby
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
JP2004507552A (ja) 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体
KR101005299B1 (ko) 2000-10-18 2011-01-04 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
ES2263687T3 (es) 2000-11-20 2006-12-16 Bristol-Myers Squibb Company Inhibidores tripeptidicos de la hepatitis c.
EP1343807B1 (fr) 2000-12-12 2009-04-29 Schering Corporation Peptides diaryliques utilises comme inhibiteurs de ns3-serine protease du virus de l'hepatite c
AU2002230764A1 (en) 2000-12-13 2002-06-24 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
WO2002048116A2 (fr) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibiteurs de la protease ns3 du virus de l'hepatite c
EP1366055A2 (fr) 2000-12-15 2003-12-03 Pharmasset Limited Agents antiviraux utilises dans le traitement des infections par les flaviviridae
CZ20032005A3 (en) 2001-01-22 2004-04-14 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
PL367348A1 (en) 2001-03-26 2005-02-21 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20030045568A1 (en) * 2001-04-20 2003-03-06 Sergio Altamura Treating hepatitis C viral infections with thiosemicarbazone compounds
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
EP1256628A3 (fr) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. ARN polymerase NS5B du virus de la hepatite C et mutants derivés de la polymerase
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
CN101624391A (zh) 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
WO2002100846A1 (fr) 2001-06-11 2002-12-19 Shire Biochem Inc. Composes et methodes de traitement ou de prevention d'infections a flavivirus
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
ATE463478T1 (de) 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
CA2461212C (fr) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, sels correspondant et agents immunosuppresseur utilisant ces derives
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
WO2003061567A2 (fr) 2002-01-18 2003-07-31 Merck & Co., Inc. Antagonistes sélectifs du récepteur s1p1/edg1
CA2472715A1 (fr) 2002-01-18 2003-07-31 Merck & Co., Inc. Agonistes du recepteur edg
MXPA04011384A (es) * 2002-05-16 2005-02-14 Novartis Ag Uso de agentes de union del receptor edg en cancer.
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
JP2005533852A (ja) * 2002-07-18 2005-11-10 セレテック エルエルシー Ｅｄｇ−１受容体に関連した症状の治療方法
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
WO2004046095A1 (fr) 2002-11-19 2004-06-03 Achillion Pharmaceuticals, Inc. Aryl thio-urees substituees et composes analogues, inhibiteurs de la replication virale
AR044402A1 (es) 2003-05-19 2005-09-14 Irm Llc Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
WO2005067454A2 (fr) 2003-12-23 2005-07-28 Valeant Pharmaceuticals North America Polytherapie pour le traitement de l'infection par le virus de l'hepatite c
GB2411114B (en) 2004-02-19 2006-08-16 Phynova Ltd A botanical drug or dietary supplement
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (fr) 2004-05-05 2005-12-01 Adler, Richard, S. Systemes et techniques de protection d'un bateau contre des attaques en surface ou sous l'eau
AU2008350851A1 (en) 2008-02-19 2009-08-27 Gambro Lundia Ab An extracorporeal fluid circuit

Also Published As

Publication number Publication date
CN101090716A (zh) 2007-12-19
WO2006072562A1 (fr) 2006-07-13
AU2006204524B2 (en) 2010-05-27
BRPI0606370A2 (pt) 2009-06-23
CN101879152A (zh) 2010-11-10
RU2007129673A (ru) 2009-03-10
US20100317627A1 (en) 2010-12-16
AU2006204524A1 (en) 2006-07-13
EP2351560A1 (fr) 2011-08-03
JP2008526714A (ja) 2008-07-24
EP1835899A1 (fr) 2007-09-26
GB0500020D0 (en) 2005-02-09
AU2006204524B8 (en) 2010-09-23
CA2592883A1 (fr) 2006-07-13
AU2010201591A1 (en) 2010-05-13
US20080207567A1 (en) 2008-08-28
KR20070091316A (ko) 2007-09-10

Similar Documents

Publication Publication Date Title
MX2007008158A (es) Tratamiento de trastornos por el virus de hepatitis c.
NL301145I2 (nl) Tirbanibulin
HK1221956A1 (zh) 用於治療感染的鹵代類苯酞化硼
EP1865967A4 (fr) Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL176142A (en) Processes for preparing montelukast sodium
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
TW200731484A (en) Integrated micro-channels for 3D through silicon architectures
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
NO20080622L (no) Disykloalkylurea-glukokinase aktivatorer
EP1868628A4 (fr) Composes, compositions et methodes de traitement des infections a poxvirus
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX2008001538A (es) Aril piridinas y metodos para su uso.
UA95247C2 (ru) Пиримидиновые соединения как модуляторы рецептора серотонина
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MY146506A (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
IL186748A0 (en) 4 - phenyl - 5 - oxo 1, 4, 5, 6, 7, 8 - hexahydroquinoline derivatives for the treatment of infertility
DK1879580T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolinderivater som lægemidler til behandling af infertilitet
DK1879581T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater som lægemidler til behandling af infertilitet
TW200716561A (en) P38 inhibitors and methods of use thereof
EP2099458A4 (fr) Composés et procédés pour imagerie et thérapie de tumeurs médiées par des enzymes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal